

Corporate Finance News

# M&A Transaction Highlights 2020

























Commerzbank successfully advised its clients on a wide range of M&A deals in the last 12 months amid COVID-19 pandemic – Commerzbank scores top league table position in terms of deal count in Germany



Despite the standstill of global M&A markets sparked by the COVID-19 pandemic in spring 2020, Commerzbank has successfully **completed 26 M&A transactions\*** in the German speaking markets, leading to a **#3 league table position in Germany\*** (deal count). Transactions included **sell-side and buy-side deals** in our core sectors Healthcare, Chemicals, Industrials, TMT, Automotive, and Consumer as well as **recap solutions** for our clients through the German WSF Economic Stabilization Fund. Moreover, Commerzbank has – despite

still prevailing negative COVID-19 market environment – a **strong and resilient pipeline of M&A projects and leads for 2021** resulting from our unmatched and longstanding **proximity to “Corporate Germany”**. In addition, Commerzbank once again proved its **in-depth reach into Asia**, which was also demonstrated by i. a. our advice to Bayer on two landmark transactions where Bayer sold state-of-the-art drug substance and filing facilities to Chinese WuXi Biologics.

**Selected M&A transactions advised by Commerzbank in 2020:**

  Sale of a German large scale biologics drug substance manufacturing facility to WuXi Biologics  <b>Financial Adviser</b>  Signed	  Advising Novum Hospitality GmbH on the recapitalization through the Economic Stabilization Fund (WSF)  <b>Financial Adviser</b>  December 2020	  Sale of majority stakes in Zytomed Systems GmbH, ZytoVision GmbH and 42 life sciences GMBH & Co. KG to ArchiMed SAS  <b>Financial Adviser</b>  December 2020	  Sale of a MDV group to Arjobex SAS, a portfolio company of Prudentia Capital  <b>Financial Adviser</b>  December 2020	  Sale of a majority stake in iPoint-systems gmbh to GRO Capital A/S  <b>Financial Adviser</b>  November 2020	  Sale of the three assets: C.W. Haarfeld GmbH, „Personalwirtschaft“ business, German congress business  <b>Financial Adviser</b>  November 2020
  Advising GNYK on the recapitalization through the Economic Stabilization Fund (WSF)  <b>Financial Adviser</b>  October 2020	  Acquisition of Lanxess' organic leather chemicals business by TFL Ledertechnik GmbH  <b>Financial Adviser</b>  August 2020	  Acquisition of GUS Group  <b>Financial Adviser</b>  August 2020	  Acquisition of BRAUN CarTec Group  <b>Financial Adviser</b>  August 2020	  Sale of WATERKOTTE GmbH to NIBE Industrier AB  <b>Financial Adviser</b>  April 2020	  Sale of a German fill & finish drug product facility to WuXi Biologics Inc.  <b>Financial Adviser</b>  April 2020

**FRANKFURT** | **LONDON** | **NEW YORK** | **HONG KONG** | **TOKYO**

\*Source: Commerzbank data and Mergermarket, incl. not disclosed Commerzbank deals, excl. accounting firms/M&A networks.

[E-mail our Team](#)

Please click [here](#) if you want to subscribe to our Commerzbank Corporate Finance News. | [Disclaimer](#)